15612023

Source:http://linkedlifedata.com/resource/pubmed/id/15612023

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0085405, umls-concept:C0123931, umls-concept:C0205179, umls-concept:C0282460, umls-concept:C0701185, umls-concept:C2931822
pubmed:issue	3
pubmed:dateCreated	2005-2-1
pubmed:abstractText	This Phase II study was designed to evaluate the efficacy and safety of irinotecan in patients with advanced nasopharyngeal carcinoma (NPC).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BalramChowbayC, pubmed-author:CheungYin-BunYB, pubmed-author:LeongSwan-SwanSS, pubmed-author:PoonDonaldD, pubmed-author:TanEng-HuatEH
pubmed:copyrightInfo	(c) 2004 American Cancer Society
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	103
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	576-81
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:15612023-Adult, pubmed-meshheading:15612023-Aged, pubmed-meshheading:15612023-Antineoplastic Agents, Phytogenic, pubmed-meshheading:15612023-Camptothecin, pubmed-meshheading:15612023-Carcinoma, pubmed-meshheading:15612023-Diarrhea, pubmed-meshheading:15612023-Disease Progression, pubmed-meshheading:15612023-Drug Administration Schedule, pubmed-meshheading:15612023-Female, pubmed-meshheading:15612023-Humans, pubmed-meshheading:15612023-Male, pubmed-meshheading:15612023-Middle Aged, pubmed-meshheading:15612023-Nasopharyngeal Neoplasms, pubmed-meshheading:15612023-Neoplasm Staging, pubmed-meshheading:15612023-Neutropenia, pubmed-meshheading:15612023-Quality of Life, pubmed-meshheading:15612023-Salvage Therapy, pubmed-meshheading:15612023-Survival Analysis, pubmed-meshheading:15612023-Treatment Outcome
pubmed:year	2005
pubmed:articleTitle	Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
pubmed:affiliation	Department of Medical Oncology, National Cancer Center, Singapore.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II